Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the BREVACTA study of RoACTEMRA (tocilizumab, known as ACTEMRA outside Europe) given as a subcutaneous (SC) injection to patients with ...

Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening In a global study, ...

Roche receives EU approval for new subcutaneous formulation of RoACTEMRA providing more treatment flexibility for patients with moderate to severe rheumatoid arthritis First anti IL-6 receptor ...

(RTTNews) - Roche (RHHBY) said FDA has approved Actemra/RoActemra subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated ...

Statistically significant greater improvement in signs and symptoms, as measured by mean change in DAS28 (primary endpoint), DAS28 remission and low disease activity, ACR20, 50 and 70 (secondary ...

Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe ...

Patients with rheumatoid arthritis (RA) in Europe are a giant step closer to receiving access to a subcutaneous formulation of Roche/Chugai's RoActemra, following the thumbs up from the European ...

Roche is celebrating two new approvals in the EU, including Actemra/RoActemra (tocilizumab), which becomes the first therapy approved in Europe to treat giant cell arthritis (GCA). GCA is a chronic ...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and has granted Priority Review for Actemra/RoActemra ...

Basel, 25 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous ...

Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease ...